The multistep process of colon carcinogenesis

L A Aaltonen1

  • 1Department of Medical Genetics, University of Helsinki, Finland.

Cytokines and Molecular Therapy
|June 1, 1996
PubMed

Insights

Colorectal tumorigenesis is a multistep process involving oncogene activation and tumor suppressor gene inactivation. Further research aims to identify molecular markers for improved colorectal cancer diagnosis and prognosis.

Area of Science:

  • Molecular biology
  • Oncology
  • Genetics

Background:

  • Colorectal cancer development involves complex molecular genetic events.
  • These events include the activation of oncogenes and inactivation of tumor suppressor genes.
  • While many genetic changes are documented, others remain unclear or unidentified.

Purpose of the Study:

  • To document molecular genetic events in colorectal tumorigenesis.
  • To identify molecular markers for clinical application in colorectal cancer.
  • To advance diagnostic tools and prognostic markers for patient management.

Main Methods:

  • Review of existing literature on molecular genetic events in colorectal cancer.
  • Analysis of studies documenting gene activation and inactivation.
  • Synthesis of data on colorectal tumor progression.

Main Results:

  • Colorectal tumorigenesis is confirmed as a multistep process.
  • Key molecular events involve oncogene activation and tumor suppressor gene inactivation.
  • Significant gaps in knowledge persist regarding all genetic alterations.

Conclusions:

  • Ongoing studies are crucial for understanding tumor initiation and progression.
  • Development of molecular markers holds promise for clinical use.
  • Molecular genetic insights will eventually enhance colorectal cancer patient management.

Related Concept Videos

Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...